Theranostics: What it is & how it impacts cancer treatmentEmpowering precision oncology from discovery to recovery
The science behind theranostics
Radioligands
A radioligand is comprised of a radioisotope that binds the specific receptors or targets, allowing visualization and quantification of these cells.
Ligands
A ligand is a molecule that is designed to bind to a target receptor or biomarker on cancer cells. This binding can be used to deliver a drug directly to cancer cells.
What it means to you and your patients
With theranostics, your patients may have:
- Treatment plans to their individual cancer characteristics
- Targeted therapy that may offer more effective tumor destruction while minimizing damage to healthy tissue
- Improved monitoring and more timely interventions
Not every patient is right for theranostics. However, when the right patients are selected, you may:
- Tailor treatment plans to an individual tumor's molecular characteristics
- Spare healthy tissues and reduce side effects
- Monitor and adjust the treatment plan to maximize its effectiveness
Types of cancer treated with theranostics
Theranostics already plays a key role in the management of prostate cancer, neuroendocrine tumors, thyroid cancer, and liver cancer.
Did this information help you?
1
Data on file.
